Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash Flows From Operating Activities:
Net loss for the period	$ (46,787)	$ (21,612)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	6,047	12,994
Depreciation expense	2,222	989
Non-cash lease expense	1,295	1,131
Foreign exchange gain	(117)	(27)
Net accretion of marketable securities	(1,006)	(2,908)
Gain on sale of technology and other assets	(5,666)	0
Changes in operating assets and liabilities:
Prepaid expenses	3,006	(1,024)
Other current receivables	67	910
Other non-current assets	179	89
Accounts payable	382	4,785
Accrued expenses and other current liabilities	(7,652)	(1,731)
Operating lease liability, current portion	(1,223)	(401)
Income taxes	609	940
Operating lease liability, net of current portion	(88)	(765)
Deferred collaboration cost recovery	3,257	0
Deferred revenue	0	(11,952)
Net cash used in by operating activities	(45,475)	(18,582)
Cash Flows From Investing Activities:
Proceeds from sale of technology and other assets	1,000	0
Proceeds from maturities of marketable securities	73,662	89,015
Purchase of marketable securities	(46,456)	(102,213)
Net cash provided by (used in) investing activities	28,206	(13,198)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	0	17
Proceeds from issuance of common stock under the 2020 Employee Share Purchase Plan	79	358
Net cash provided by financing activities	79	375
Effect of exchange rate fluctuations on cash held	129	(43)
Net Decrease In Cash And Cash Equivalents	(17,061)	(31,448)
Cash and cash equivalents at beginning of period	84,717	111,268
Cash and cash equivalents at end of period	67,656	79,820
Supplemental Disclosure Of Cash Flow Information:
Non-cash consideration received from sale of technology and other assets - Investment in equity securities	1,591	0
Non-cash consideration received from sale of technology and other assets - Derivative financial asset	600	0
Consideration receivable from sale of technology and other assets - Other current receivables	3,000	0
Contracts transferred to acquirer as part of sale of technology and other assets - Prepaid expenses	$ (525)	$ 0

Repare Therapeutics Inc. 10-Q